IPEN will provide 18F-FDG for five hospitals of SP that meet users of SUS
Cooperation agreement with the Secretariat of health of the State of São Paulo ensures 4600 doses a year to five hospitals, among them, the A.C. Camargo.
Warning: This content was machine translated and is scheduled for reviewing.
Agreement signed between the IPEN/CNEN-SP and the State Secretariat of health of São Paulo will enable the provision of radiopharmacology 18F-FDG (marked fluordesoxiglicose with fluorine-18) for users of the unified health system (SUS) in the region. Are R$ State Health Fund 2,400,000, intended for funding, i.e. consumables. The resources will enable greater access to Imaging tests with PET/CT in public hospitals and foundations, dose/4600 year ensuring that 18F-FDG distributed to five hospitals.
According to Jair Mengatti, Radiofarmácia Center Manager (CR) of IPEN, the main objective of this agreement is to strengthen the development of health care services provided to patients of the SUS. A priori, five institutions will benefit: the Hospital das Clínicas da Universidade Estadual de Campinas and the Boldrini child Center for cancer and blood Diseases, both in Campinas, in addition to the Hospital of Heliopolis and A.C. Camargo, in the city of São Paulo, and the Cancer Hospital Amaral Carvalho, in the city of Jaú (located 296 km from the capital).
"We're going to offer these 4600 doses per year, which will be distributed in dimensions to these hospitals, according to criteria established by the Board of health. Are the five institutions that provide broader assistance to patients of the SUS, "said Jair.
Advantage
The agreement, signed in late April, has duration of one year-this first deal is worth until December 2016, and may be renewed every year by the interest of both partners. The financial resources will not be transferred directly, according to the Manager of the CR.
"The resources will be allocated to the purchase of inputs to the production of this radiopharmacology, i.e. There is no direct allocation of funds to the IPEN. The big advantage is that, as resources for funding, we will be able to buy other inputs, to develop other radiopharmaceuticals mainly of Cyclotron ", he added.
Wilson Calvo, Director of administration of IPEN, highlights the "valuable cooperation with the Department of health and the opportunity to work together to promote growth and development in research and in applications of nuclear medicine with radioisotopes produced at the Radiofarmácia Center of the Institute. That's great news for us, that there are times we used to fighting for it, and for users of SUS ".
---------
Also available in Orbit May-June 2016
